Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 894 participants.
Also called NCT01768559
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 894 participants
- Sponsor
- Registry
-
NCT01768559 -
2012-004096-38
-
- Main results
- Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Chile, Czechia, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russia, Spain, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01768559. Randomized; no masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2017-01-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
- Acronym
- GetGoal-Duo-2
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Drug)
- Insulin glulisine QD
- Intervention (Drug)
- Insulin glulisine TID
- Intervention (Drug)
- Insulin Glargine (Mandatory background drug)
- Intervention (Drug)
- Metformin (Background drug)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01768559- Content hash
eed81416351900916398ffe8b010ac8dc22d48bcef2eeaa1324643ab8efb442b